Home / Healthcare/ AstraZeneca’s key lung cancer drug wins European panel thumbs-up

AstraZeneca’s key lung cancer drug wins European panel thumbs-up


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 31 July 2018 00:00


Reuters: AstraZeneca’s cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

While final approvals are up to the European Commission, it generally follows the CHMP’s recommendation and endorses them within a couple of months.

The US Food and Drug Administration (FDA) in February granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

Japan also approved the drug earlier this month.

The latest green light - which had been expected after positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Globally, about 30% of patients with NSCLC present with stage III disease. These individuals typically receive a combination of chemotherapy and radiotherapy, but only around 15% of them are still alive after five years.

Imfinzi, chemically known as durvalumab, belongs to a new class of immuno-oncology drugs that block a mechanism tumors use to evade detection from the immune system.

AstraZeneca’s drug already had approval for treating certain patients with bladder cancer. However, this market is relatively small.

The really big opportunity for all companies seeking to exploit the power of modern immuno-oncology drugs is lung cancer, since it is the leading cause of cancer deaths.

Bristol-Myers Squibb, Roche and Merck all have approved products for treating certain patients with advanced lung cancer - but AstraZeneca is now in a position to carve out a niche in treating earlier stage III patients.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Untruth is the crisis

Tuesday, 13 November 2018

Political language, said George Orwell, is designed to make lies sound truthful, murder respectable, and to give an appearance of solidity to pure wind. Dr. Sarath Amunugama is the subject of this essay. In addition to his current incarnation of a p


Rise, Sri Lankans – our country needs you now!

Tuesday, 13 November 2018

I am sick, tired and bloody fed up of reading and listening to pessimistic tales of woe on the unprecedented crisis we and our country are facing at this dark moment in time. I am also fed up to the back teeth with reading and listening to lamentatio


Ranil abused and subverted parliamentary democracy

Tuesday, 13 November 2018

TIME: What was the immediate reason for calling an election? President Kumaratunga: I was forced into it by a total breakdown of cohabitation in Government. The Prime Minister (Ranil Wickremesinghe) was determined to harass me and chase me out. He ha


The Bench must ensure that the judges will continue to be trusted

Monday, 12 November 2018

In the backdrop of the recent developments and the strong arguments that have been presented against the dissolution of Parliament saying the President has no constitutional power to do so, before four and a half years into a Parliamentary term, as s


Columnists More